Laura

🚨 ESMO updates metastatic pancreatic cancer guidance: daraxonrasib enters the algorithm. In previously treated RASG12-mutated metastatic PDAC, ECOG PS 0–1, ESMO now recommends daraxonrasib monotherapy after chemotherapy failure [I, A]. 📌 RASolute 302 Daraxonrasib 300 mg OD vs investigator-choice chemotherapy in previously treated metastatic PDAC. 📊 RASG12-mutated population • OS: 13.2 vs 6.6 months HR 0.40, P<0.001 • PFS: 7.3 vs 3.5 months HR 0.45, P<0.001 • ORR: 33.2% vs 11.8% 💡 Why it matters RAS has long been one of pancreatic cancer’s hardest targets. Daraxonrasib produced a striking survival advantage and has now moved into the ESMO treatment algorithm. ⚠️ Evidence is strongest for RASG12-mutated, ECOG 0–1 disease. Benefit in RASG13, RASG61 and RAS-wild-type tumors remains uncertain. @ASCO @oncoalert #PancreaticCancer #KRAS #PrecisionOncology #Oncology

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC 3️⃣ HARMONi-6 Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC 4️⃣ RASolute 302 Daraxonrasib (RMC-6236) in metastatic pancreatic cancer 5️⃣ SARC041 Abemaciclib in dedifferentiated liposarcoma ⚡ FRONTLINE & PERIOPERATIVE SHIFTS 6️⃣ KEYNOTE-B15 / EV-304 EV + pembrolizumab vs chemo in MIBC 7️⃣ LITESPARK-022 Pembrolizumab + belzutifan in adjuvant ccRCC 8️⃣ AMBITION Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer 9️⃣ NeoADAURA Neoadjuvant osimertinib in EGFR+ NSCLC 🔟 A-DREAM ADT interruption strategies in mCSPC 🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY 1️⃣1️⃣ DESTINY-Breast06 T-DXd expands into HER2-ultralow disease 1️⃣2️⃣ CROWN (7-year update) Lorlatinib durability in ALK+ NSCLC 1️⃣3️⃣ DeLLphi-312 Tarlatamab in frontline SCLC 1️⃣4️⃣ COMMIT Atezolizumab + FOLFOX/Bev in MSI-H mCRC 1️⃣5️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in bladder cancer #OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers